(Q38205268)

31 August 2017

title

Teriflunomide: a novel oral treatment for relapsing multiple sclerosis (English)

1 reference

31 August 2017

0 references

Arianna Sartori

1

1 reference

31 August 2017

Dawn Carle

series ordinal

2

1 reference

31 August 2017

Mark S Freedman

series ordinal

3

1 reference

31 August 2017

language of work or name

English

0 references

publication date

17 April 2014

1 reference

Expert Opinion on Pharmacotherapy

31 August 2017

published in

1 reference

31 August 2017

volume

15

1 reference

31 August 2017

issue

7

1 reference

31 August 2017

page(s)

1019-1027

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.902936

31 August 2017

1 reference

Fingolimod for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.902936

Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.902936

Excitability out of balance: treating hemineglect with transcranial magnetic brain stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.902936

Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.902936

Placebo-controlled trial of oral laquinimod for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.902936

The effects of teriflunomide on lymphocyte subpopulations in human peripheral blood mononuclear cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.902936

Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.902936

Immune mechanisms of new therapeutic strategies in MS: teriflunomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.902936

Teriflunomide reduces behavioral, electrophysiological, and histopathological deficits in the Dark Agouti rat model of experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.902936

A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.902936

Randomized trial of oral teriflunomide for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.902936

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.902936

Magnetic resonance imaging outcomes from a phase III trial of teriflunomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.902936

Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.902936

Teriflunomide reduces relapse-related neurological sequelae, hospitalizations and steroid use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.902936

Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.902936

Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.902936

The best clinical paper on multiple sclerosis in 2012.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.902936

Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.902936

Birth outcomes in women who have taken leflunomide during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.902936

Pregnancy outcome in women exposed to leflunomide before or during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.902936

Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.902936

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.902936

Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.902936

10.1517/14656566.2014.902936

21 January 2018

Identifiers

DOI

1 reference

31 August 2017

1 reference